A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

Inclusion Criteria:

1. Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).

2. Patient is willing and able to adhere to the study visit schedule and other protocolrequirements.

3. Patient has relapsed or primary refractory AML or MDS

4. Any other comorbidity that per the investigator renders a patient inappropriate forintensive chemotherapy.

5. Patients with MDS must be classified as MDS-IB1 or IB2 as per WHO 2022 criteria32

6. TP53Y220C mutation confirmed by CLIA-approved local testing with a variant allelefrequency >2%.

7. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2

8. Patient has adequate organ function defined as:

• Serum aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3 x ULN, unless considereddue to leukemic organ involvement.

• Serum total bilirubin ≤ 1.5 x ULN. Higher levels are acceptable if these can beattributed to ineffective erythropoiesis, leukemia organ involvement orGilbert's syndrome.

• Serum creatinine < 2 x ULN or creatinine clearance > 40 mL/min based onvalidated glomerular filtration rate (GFR) estimation (Cockcroft-Gault,CKD-epi, or MDRD equations).

9. Females of childbearing potential may participate provided they have a negativeserum or urine pregnancy test at screening and a negative serum OR urine pregnancytest within 72 hours of starting on treatment. They also must agree to eitherabstain from sexual intercourse or use two forms of a highly effective method ofcontraception while on study and up to 3 months after the last dose of the studydrug.

10. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) 14 days prior to studyentry and for the duration of study participation. This includes all female patientsbetween the onset of menses and 55 years unless the patient presents with anapplicable exclusionary factor which may be one of the following: Postmenopausal (no menses in greater than or equal to 12 consecutive months).History of hysterectomy or bilateral salpingo-oophorectomy. Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have receivedWhole Pelvic Radiation Therapy). History of bilateral tubal ligation or another surgical sterilization procedure.

• Approved methods of birth control are as follows: Hormonal contraception (i.e.birth control pills, injection, implant, transdermal patch, vaginal ring),Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner postvasectomy, Implantable or injectable contraceptives, and condoms plus spermicide.Not engaging in sexual activity for the total duration of the trial and the drugwashout period is an acceptable practice; however periodic abstinence, the rhythmmethod, and the withdrawal method are not acceptable methods of birth control.Should a woman become pregnant or suspect she is pregnant while she or her partneris participating in this study, she should inform her treating physicianimmediately. Men treated or enrolled on this protocol must also agree to use adequatecontraception prior to the study, for the duration of study participation, and 3months after completion of investigational agent administration.

11. Ability to understand and the willingness to sign a written informed consentdocument.

Exclusion Criteria:

1. Patient has received prior chemotherapy, targeted therapy, immunotherapy, ortreatment with an investigational anticancer agent within 14 days or 5 half-lives (if half-life is known), whichever is shorter, before receiving their first dose ofstudy drug.

2. Patient has received radiotherapy within 14 days.

3. Patients with acute promyelocytic leukemia

4. Subject has immediate life-threatening, severe complications of leukemia such asuncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminatedintravascular coagulation.

5. Patients with active, uncontrolled leukemia involvement of the CNS

6. Subject has known active viral infection with human immunodeficiency virus (HIV), oractive infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)

7. Subject is known to have dysphagia, short-gut syndrome, gastroparesis, or otherconditions that limit the ingestion or gastrointestinal absorption of drugsadministered orally.

8. Subject has active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvementdespite appropriate antibiotics, antiviral therapy, and/or other treatment).

9. Patient has any unresolved toxicities from prior anti-cancer therapy greater thanGrade 1 at the time of starting study treatment with the exception of alopecia andGrade 2 prior chemotherapy induced neuropathy.

10. Patient has had major surgery within 2 weeks prior to the planned start of studytreatment.

11. Female subject who is pregnant or lactating.

12. History of allergic reactions attributed to compounds of similar chemical orbiologic composition to azacitidine, rezetapopt or other agents used in study.